/NOT FOR DISTRIBUTION IN THE
UNITED STATES OR THROUGH UNITED
STATES WIRE SERVICES./
TORONTO,
March 28, 2014 /CNW/ - Microbix
Biosystems Inc. (TSX: MBX), an innovator of biological products and
technologies, is pleased to announce it has made application to the
TSX to extend the term of an aggregate of 2,990,641 common share
purchase warrants (the "Warrants") which were issued in connection
with Microbix' March 29, 2012
non-brokered private placement.
Each Warrant currently entitles the holder to
purchase one common share of Microbix at a price of $0.40 until March
29, 2014. Microbix has applied to the TSX to extend the
term of the Warrants and Finders Warrants to March 29, 2015.
The holders of the Warrants includes both
insiders of Microbix and parties who are arm's length to
Microbix. Insiders of Microbix will not be permitted to
exercise their warrants unless and until disinterested shareholder
approval is obtained. The extension to the term of the
Warrants is subject to TSX approval.
The Toronto Stock Exchange does not accept
responsibility for the adequacy or accuracy of this release.
About Microbix Biosystems
Microbix
Biosystems Inc. specializes in the development of biological
solutions, including products for vaccine and diagnostics markets
worldwide. The company owns intellectual property for an
approved biological drug, a vaccine technology and an animal
reproduction technology. Established in 1988, Microbix is
headquartered in Toronto.
Microbix' pipeline of innovative technologies and
products includes LumiSort® semen sexing technology for the
livestock industry, Kinlytic®, a thrombolytic drug with several
approved and potential applications including the treatment of
life-threatening blood clots, and VIRUSMAX®, a proprietary
technology for increasing virus yields in influenza vaccine
manufacture.
Disclaimer
This press release may
contain forward-looking statements which are subject to risks and
uncertainties that could cause actual results to differ materially
from those set forth in the forward-looking statements including
the risks associated with litigation, operations in foreign
jurisdictions, foreign currency and exchange rate risk, and risks
of raising capital on acceptable terms or at all. These
statements reflect management's current estimates, beliefs,
intentions and expectations; they are not guarantees of future
performance. The Company cautions that all forward-looking
information is inherently uncertain and the actual performance may
be affected by a number of material factors, many of which are
beyond the Company's control. Accordingly, actual future
events, conditions and results may differ materially from the
estimates, beliefs, intentions and expectations expressed or
implied in the forward-looking information. All statements
are made as of the date of this news release. The Company is
under no obligation to update or alter any forward-looking
information.
Please visit www.sedar.com for recent Microbix Biosystems Inc.
filings on its pipeline products and financial information.
SOURCE Microbix Biosystems Inc.